Attralus to Present New AT-01 Data at 2022 Society of Nuclear Medicine & Molecular Imaging Annual Meeting
03 juin 2022 08h00 HE
|
Attralus, Inc
Final Phase 1/2 Study Results for AT-01 (Evuzamitide), Attralus's Novel Pan-Amyloid Imaging Agent for the Detection of Systemic Amyloidosis Repeat PET/CT Imaging of a Patient with Systemic Amyloidosis...
Positive New Data from Phase 1/2 Trial of AT-01 Presented at 2022 American College of Cardiology Annual Scientific Session
04 avr. 2022 08h00 HE
|
Attralus, Inc
AT-01 is a first-in-class pan-amyloid imaging agent capable of detecting diverse types of amyloidSensitivity in those with previously diagnosed cardiac disease was 100% in ATTR and 93% in ALCardiac...
Attralus Appoints James Testa as Vice President of Finance
10 févr. 2022 08h00 HE
|
Attralus, Inc
SAN FRANCISCO, Feb. 10, 2022 (GLOBE NEWSWIRE) -- Attralus, Inc., a clinical stage biopharmaceutical company developing transformative medicines to improve the lives of patients with systemic...
Attralus Presents Positive New Data at 2021 American Society of Hematology Annual Meeting
13 déc. 2021 08h00 HE
|
Attralus, Inc
AT-03 potently binds human AL and ATTR fibrils and is capable of binding diverse forms of systemic amyloid deposits in mouse models AT-03 enhances macrophage-mediated phagocytosis of AL amyloid...
Attralus to Present at Piper Sandler 33rd Annual Virtual Healthcare Conference
22 nov. 2021 08h00 HE
|
Attralus, Inc
SOUTH SAN FRANCISCO, Calif., Nov. 22, 2021 (GLOBE NEWSWIRE) -- Attralus, Inc., a clinical stage biopharmaceutical company developing transformative medicines to improve the lives of patients with...
Attralus to Present New Data at 2021 American Society of Hematology Annual Meeting
04 nov. 2021 09h00 HE
|
Attralus, Inc
SOUTH SAN FRANCISCO, Calif., Nov. 04, 2021 (GLOBE NEWSWIRE) -- Attralus, Inc., a clinical stage biopharmaceutical company developing transformative medicines to improve the lives of patients with...
Attralus Closes $116 Million Series B Financing
08 sept. 2021 07h00 HE
|
Attralus, Inc
- Proceeds to advance pipeline of transformational pan-amyloid removal (PAR) therapeutics into the clinic - Financing led by Logos Capital and included other leading public healthcare funds - ...
Attralus Appoints Jake Bauer to Board of Directors
28 juil. 2021 07h00 HE
|
Attralus, Inc
SOUTH SAN FRANCISCO, Calif., July 28, 2021 (GLOBE NEWSWIRE) -- Attralus, Inc., a clinical stage biopharmaceutical company developing transformative medicines to improve the lives of patients with...